Phase II trial of dacomitinib, a pan–human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification

BACKGROUND: We conducted a multicenter, 2-stage, open-label, phase II trial to assess the efficacy and safety of dacomitinib in adult patients with recurrent glioblastoma (GB) and epidermal growth factor receptor gene (EGFR) amplification with or without variant III (EGFRvIII) deletion. METHODS: Pat...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neuro Oncol
Prif Awduron: Sepúlveda-Sánchez, Juan Manuel, Vaz, María Ángeles, Balañá, Carmen, Gil-Gil, Miguel, Reynés, Gaspar, Gallego, Óscar, Martínez-García, María, Vicente, Elena, Quindós, María, Luque, Raquel, Ramos, Ana, Ruano, Yolanda, Pérez-Segura, Pedro, Benavides, Manuel, Sánchez-Gómez, Pilar, Hernández-Laín, Aurelio
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2017
Pynciau:
Clinical Investigations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5737732/
https://ncbi.nlm.nih.gov/pubmed/28575464
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox105
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg